A dual agonist is a single molecule designed to activate two different hormone receptors at the same time. In the world of metabolic medicine, this usually means targeting the receptors for gut hormones that help regulate blood sugar, appetite, and weight. By switching on two pathways instead of one, a dual agonist can produce broader effects than a medication that targets only a single receptor. The best known example is tirzepatide, which activates both the GLP-1 receptor and the GIP receptor. It is FDA-approved for type 2 diabetes under the name Mounjaro and for obesity under the name Zepbound.
Other dual agonists combine GLP-1 activity with glucagon activity, including survodutide, which is in Phase 3 trials and holds FDA fast-track designation for the liver disease MASH, and mazdutide, which is already approved in China for weight management and type 2 diabetes but is not yet FDA-approved in the United States. The reasoning behind this approach is that hitting two receptors can deliver greater weight loss and metabolic benefit than a single agonist alone. Interest in addiction recovery comes from a related insight, because these same gut hormone signals reach the brain. GLP-1 and related incretin receptors sit within the mesolimbic dopamine system, the network that drives reward and motivation. Early research suggests that influencing this system may help quiet cravings, which is why dual agonists are being explored as a possible future tool in recovery, always under medical supervision and never as a substitute for professional care.
How Do Dual Agonists Work And Which Ones Exist Today?
Dual agonists work by mimicking natural gut hormones that your body releases after eating. When a single molecule binds to two receptors, such as the GLP-1 and GIP receptors, it can amplify the signals that lower blood sugar, slow stomach emptying, and reduce appetite. Pairing two complementary pathways is meant to outperform a single-target drug, which is the central rationale behind this newer class of medications. Tirzepatide is the clearest success story so far, having earned FDA approval first for type 2 diabetes in 2022 and then for obesity in 2023.
Beyond tirzepatide, the field is expanding quickly. Survodutide, a GLP-1 and glucagon dual agonist, has advanced into Phase 3 testing and received FDA fast-track status for MASH, a serious form of fatty liver disease, though it remains investigational. Mazdutide, another GLP-1 and glucagon combination, is already approved in China for both weight management and type 2 diabetes, but it is not yet FDA-approved in the United States. None of these medications is FDA-approved specifically for treating addiction, so any role in recovery remains an area of ongoing research.
Could Dual Agonists Help With Cravings In Recovery?
The curiosity around dual agonists and addiction grows out of where these hormones act in the body. GLP-1 and related incretin receptors are present not only in the gut and pancreas but also in the brain, including the mesolimbic dopamine reward system. This is the same circuitry that fuels the powerful urges and reward-seeking behavior at the heart of substance use disorders. Emerging research suggests that incretin signaling may dampen cravings and reduce reward-driven behavior, and these early signals have appeared across alcohol, nicotine, opioids, and other substances.
Because dual agonists act on two receptors that both touch this reward system, scientists are asking whether they might offer even broader benefit than single agonists for people in recovery. For now, this remains investigational, and the evidence is early rather than settled. No dual agonist is FDA-approved for addiction, and these medicines should only ever be used under the guidance of a qualified medical team. This page is educational and is not medical advice. At Carrara Treatment, care is grounded in proven, evidence-based therapies, while we stay attentive to promising research that may shape the future of recovery.
Frequently Asked Questions
are dual agonists fda-approved for addiction?
No. For addiction, dual agonists are investigational and not FDA-approved. Tirzepatide is FDA-approved for type 2 diabetes and obesity, survodutide is still investigational, and mazdutide is approved in China but not in the United States. Any use related to cravings or recovery is still early research, and these medicines should only be taken under medical supervision. This page is educational, not medical advice.
how might a dual agonist affect cravings?
Gut hormone receptors like GLP-1 are present in the brain’s mesolimbic dopamine reward system, the network behind cravings. Early evidence suggests incretin signaling may reduce reward-driven behavior across alcohol, nicotine, opioids, and other substances. Because a dual agonist activates two of these receptors, researchers are studying whether it could help quiet urges, though this remains investigational and unproven.
what is the difference between a single and a dual agonist?
A single agonist activates one receptor, while a dual agonist is one molecule that switches on two receptors at once. For example, tirzepatide targets both the GLP-1 and GIP receptors, and other dual agonists pair GLP-1 with glucagon. The aim is broader effect, since hitting two pathways can produce greater weight loss and metabolic benefit than targeting just one. Main side effects tend to be gastrointestinal.
